Cargando…
RANKL is a therapeutic target of bone destruction in rheumatoid arthritis
Although remarkable advances have been made in the treatment of rheumatoid arthritis (RA), novel therapeutic options with different mechanisms of action and fewer side effects have been expected. Recent studies have demonstrated that bone-resorbing osteoclasts are critically involved in the bone des...
Autor principal: | Tanaka, Sakae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480939/ https://www.ncbi.nlm.nih.gov/pubmed/31069051 http://dx.doi.org/10.12688/f1000research.17296.1 |
Ejemplares similares
-
Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020) -
Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway
por: Liu, Chunfang, et al.
Publicado: (2013) -
Cytokine-Mediated Bone Destruction in Rheumatoid Arthritis
por: Jung, Seung Min, et al.
Publicado: (2014) -
Regulation of RANKL signaling in arthritic bone destruction
por: Takayanagi, H
Publicado: (2003) -
RANKL expression in chondrocytes and its promotion by lymphotoxin-α in the course of cartilage destruction during rheumatoid arthritis
por: Takeshita, Ayumu, et al.
Publicado: (2021)